Introduction
============

Lung cancer is one of the most commonly diagnosed cancer (12.7% of the total cancer diagnoses) as well as the leading cause of cancer death (18.2% of the total cancer deaths) among all cancer patients worldwide (Mehrabi et al., 2017; Zhong et al., 2012). Lung cancer critically can be divided into two groups include Non-Small Cell Lung Carcinoma (NSCLC) and Small cell lung carcinoma (SCLC), which the first one accounts for about 80% of all lung cancers. Although, the mean onset age for lung cancer has been estimated ranged 60 to 70 years, less than 10% of all cases occurred at an early age (Rosenberger et al., 2008). Although tobacco smoke is probably the predominant etiological risk factor for lung cancer, the pathoetiology of lung cancer is not fully understood. Interestingly, lung cancer develops only in a small proportion of chain smokers (less than 11%), which indicating that genetic factors might play a critical role in its carcinogenic mechanisms (Cavic et al., 2014).

Genetic factors involved in lung cancers have been extensively studied and to date several genetic polymorphisms have been identified as candidates by meta-analyses. Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) deleterious mutations occur mutually among 5-15% of lung cancer cases (Choughule et al., 2014). The promoter region polymorphisms of *IL-10* gene has been associated with susceptibility to several cancers including lung cancer (Namazi et al., 2018; Sheikhpour et al., 2017). However, published data on the possible association of *IL-10* polymorphism with lung cancer have generated inconclusive results. For example, Zhang et al found a significant association between the *-819T\>C* and *-592A\>C* polymorphisms of IL-10 and lung cancer in a Chinese population (Zhang et al., 2015), while Hsia et al., (2014) have reported that the genotypes of*IL-10 -819TC* polymorphism may have a protective effect on lung cancer risk in a Taiwanese population. Therefore, to estimate the effect of promoter region polymorphisms of *IL-10* gene and lung cancer risk, as well as to quantify the potential between-study heterogeneity, we performed this meta-analysis based on published case-control studies.

Materials and Methods
=====================

*Search strategies*

We systematically searched several online databases including PubMed, EMBASE, Web of Science, Google Scholar, China Biological Medicine Database, and China National Knowledge Infrastructure comprehensively for all studies on the association of promoter region polymorphisms of *IL-10* gene with lung cancer up to September 15, 2018. The combinations of following keywords and terms were used: (''*lung carcinomas*'' or ''*lung adenocarcinoma*'' or ''*lung cancer*'' or ''*small cell lung cancer*'' or ''*Non-Small Cell Lung Cancer*'') and (''*-1082 G\>A*'' or ''*rs1800896*'' or ''*-819 T\>C*'' or ''*rs1800871*'' or ''*-592A\>C*'' or ''*rs1800872*'') and (''*polymorphism*'' or ''*single nucleotide polymorphism*'' or ''*variation*'' or ''*mutation*''). Moreover, the reference lists of retrieved studies were hand-searched to find out the missing studies. All analyses of this meta-analysis were based on previous published studies, and this meta-analysis did not have original data. Thus, no ethical approval and patient consent are required.

###### 

Characteristics of the Studies Included in Meta-Analysis

  First Author         Ethnicity            SOC   Genotyping   Case/Control   Cases                               Control   MAFs   HWE                                          
  -------------------- -------------------- ----- ------------ -------------- ----------- ----------- ----------- --------- ------ ----- ----------- ----- ------ ------ ------ ------
                       (Country)                  Methods                     Genotypes   Alleles     Genotypes   Alleles                                                       
  -592A\>C                                                                    AA          AC          CC          A         C      AA    AC          CC    A      C             
  Shih 2005            Taiwan(Asian)        HB    PCR-RFLP     154/205        66          70          18          202       106    116   76          13    308    102    0.24   0.9
  Colakogullari 2008   Turkey(Caucasian)    HB    PCR-SSP      44/59          2           23          19          27        61     7     25          27    39     79     0.66   0.74
  Vogel 2008           Denmark(Caucasian)   HB    PCR          403/744        13          149         241         175       631    42    250         452   334    1154   0.77   0.34
  Liang 2011           China(Asian)         HB    PCR-RFLP     116/120        69          36          11          174       58     69    44          7     182    58     0.24   0.99
  Hart 2011            Norway(Caucasian)    HB    TaqMan       434/433        15          175         243         205       661    26    144         264   196    672    0.77   0.28
  Hsia 2014            Taiwan(Asian)        HB    PCR-RFLP     358/716        173         145         40          491       225    368   277         71    1013   419    0.29   0.07
  Zhang 2015           China(Asian)         HB    PCR-RFLP     330/336        64          156         110         284       376    85    176         75    346    326    0.48   0.37
  -819T\>C                                                                    TT          TC          CC          T         C      TT    TC          CC    T      C             
  Seifart 2005         Germany(Caucasian)   HB    PCR-RFLP     77/242         2           14          24          18        62     14    88          140   116    368    0.76   0.97
  Shih 2005            Taiwan(Asian)        HB    PCR-RFLP     154/205        66          58          30          190       128    104   86          15    294    116    0.28   0.62
  Colakogullari 2008   Turkey(Caucasian)    HB    PCR-SSP      44/59          2           23          19          27        61     7     26          26    40     78     0.66   0.89
  Hsia 2014            Taiwan(Asian)        HB    PCR-RFLP     358/716        212         128         18          552       164    372   265         79    1009   423    0.29   0
  Zhang 2015           China(Asian)         HB    PCR-RFLP     330/336        108         135         87          351       309    145   144         47    434    238    0.35   0.24
  -1082A\>G                                                                   AA          AG          GG          A         G      AA    AG          GG    A      G             
  Seifart 2005         Germany(Caucasian)   HB    PCR-RFLP     39/243         6           21          12          33        45     86    115         42    287    199    0.4    0.73
  Shih 2005            Taiwan(Asian)        HB    PCR-RFLP     115/205        115         39          0           269       39     194   11          0     399    11     0.02   0.69
  Colakogullari 2005   Turkey(Caucasian)    HB    PCR-SSP      44/59          11          30          3           52        36     33    21          5     87     31     0.26   0.53
  Hao 2009             China(Asian)         PB    TaqMan       44/52          36          7 (AG+GG)               \-        \-     46    6 (AG+GG)         \-     \-     \-     
  Hart 2011            Norway(Caucasian)    HB    TaqMan       436/435        120         207         109         447       425    104   226         105   434    436    0.5    0.41
  Hsia 2014            Taiwan(Asian)        HB    PCR-RFLP     358/716        273         69          16          615       101    561   130         25    1252   180    0.12   0
  Peddireddy 2016      India(Asian)         HN    PCR-RFLP     246/250        156         69          21          381       111    130   84          36    344    156    0.31   0

###### 

Summary Risk Estimates for Association between IL-10 Polymorphism and Risk of Lung Cancer

  Subgroup     Genetic Model   Type of Model   Heterogeneity   Odds Ratio (OR)   Publication Bias                                
  ------------ --------------- --------------- --------------- ----------------- ------------------ ----------- ------- -------- ----------
                                               I^2^ (%)        P~H~              OR                 95% CI      Z~OR~   P~OR~    P~Beggs~
  -592A\>C     C vs. A         Fixed           49.9            0.06              1.14               1.03-1.25   2.68    0.007    1
               CC vs. AA       Fixed           0               0.68              1.64               1.29-2.02   4.16    ≤0.001   0.54
               CA vs. AA       Fixed           37.21           0.14              1.26               1.06-1.50   2.68    ≤0.001   0.22
               CC+CA vs. AA    Fixed           15.63           0.31              1.31               1.11-1.54   3.27    0.001    0.36
               CC vs. CA+AA    Random          62.3            0.01              1.16               0.89-1.52   1.12    0.26     0.54
  Asians       C vs. A         Fixed           43.73           0.14              1.26               1.11-1.43   3.61    ≤0.001   0.73
               CC vs. AA       Fixed           17.91           0.3               1.61               1.22-2.21   3.43    0.001    0.73
               CA vs. AA       Fixed           20.93           0.28              1.16               0.96-1.40   1.58    0.11     1
               CC+CA vs. AA    Fixed           35.76           0.19              1.25               1.04-1.49   2.49    0.01     1
               CC vs. CA+AA    Fixed           0               0.4               1.52               1.19-1.93   3.41    0.001    0.73
  Caucasians   C vs. A         Fixed           0               0.67              0.99               0.85-1.15   -0.09   0.92     1
               CC vs. AA       Fixed           0               0.89              1.7                1.09-2.65   2.36    0.01     1
               CA vs. AA       Fixed           0               0.85              2.08               1.32-3.27   3.18    0.001    0.29
               CC+CA vs. AA    Fixed           0               0.81              1.76               1.13-2.71   2.54    0.01     1
               CC vs. CA+AA    Fixed           0               0.4               1.52               1.19-1.93   3.41    0.001    0.73
  -819T\>C     T vs. C         Random          95.76           ≤0.001            0.98               0.86-1.11   -0.25   0.8      0.8
               TT vs. CC       Random          87.95           ≤0.001            1.53               0.57-4.06   0.85    0.39     0.8
               TC vs. CC       Fixed           19.96           0.28              1.01               0.84-1.22   0.16    0.87     0.8
               TT+TC vs. CC    Random          94.81           ≤0.001            0.71               0.30-1.71   -0.74   0.45     0.8
               TT vs. TC+CC    Random          92.33           ≤0.001            0.98               0.33-2.41   -0.04   0.96     0.8
  -1082A\>G    G vs. A         Random          90.8            ≤0.001            1.51               0.95-2.38   1.76    0.07     0.13
               GG vs. AA       Random          71.79           ≤0.001            1.15               0.63-2.08   0.46    0.64     0.46
               GA vs. AA       Random          88.58           ≤0.001            1.67               0.92-3.04   1.7     0.08     0.45
               GG+GA vs. AA    Random          89.81           ≤0.001            1.76               0.97-3.20   1.86    0.06     0.76
               GG vs. GA+AA    Fixed           53.87           0.07              1.02               0.81-1.30   0.23    0.81     0.8
  Asians       G vs. A         Random          95.29           ≤0.001            1.64               0.63-4.22   1.03    0.3      1
               GG vs. AA       Random          80.06           0.02              0.79               0.29-2.10   -0.46   0.64     NA
               GA vs. AA       Random          92.73           ≤0.001            1.56               0.60-4.03   0.91    0.36     1
               GG+GA vs. AA    Random          92.97           ≤0.001            1.68               0.65-4.32   1.07    0.28     0.73
               GG vs. GA+AA    Random          73.27           0.05              0.83               0.36-1.91   -0.42   0.67     NA
  Caucasians   G vs. A         Random          82.69           0.003             1.46               0.82-2.59   1.31    0.18     1
               GG vs. AA       Random          73.42           0.02              1.72               0.59-5.00   1       0.31     1
               GA vs. AA       Random          87.66           ≤0.001            1.95               0.61-6.24   1.13    0.25     1
               GG+GA vs. AA    Random          87.64           ≤0.001            1.99               0.65-6.08   1.21    0.22     1
               GG vs. GA+AA    Fixed           36.07           0.2               1.14               0.86-1.51   0.93    0.35     1
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*Inclusion and exclusion criteria*

Inclusion criteria were: 1) studies with case-control or cohort design; 2) evaluation of association of promoter region polymorphisms of IL-10 gene with lung cancer risk; 3) provided sufficient data to calculate the odds ratios (ORs), 95% confidence intervals (CIs). Accordingly, exclusion criteria were: 1) linkage studies or family based studies; 2) studies did not provided genotype frequencies; 3) duplicates or overlapping data; and 4) abstracts, reviews, meta-analyses, case reports, editorials, and animal studies.

*Data extraction*

The identified studies were reviewed separately by two authors independently and carefully to extraction necessary data and then recorded in a standardized form. We have resolved any disagreement by a discussion with the senior investigator. We sought the following data from each study: first author's name, year of publication, ethnicity of each study population, country, source of controls, genotyping method, number of cases and controls, as well as numbers of cases and controls for *IL-10* polymorphisms, minor allele frequency (MAF) in healthy subjects, and evidence of Hardy-Weinberg equilibrium (HWE).

*Statistical analysis*

All of the calculations were performed using Comprehensive Meta-Analysis (CMA) version 2.0 (Biostat, USA). Two-sided P-values\<0.05 were considered statistically significant. The strength of association of promoter region polymorphisms of IL-10 gene with lung cancer risk was assessed using ORs and 95%CIs. The Z-test was employed to determine the significance of the pooled ORs.

Pooled ORs were calculated under four genetic models, i.e., allele (B vs. A), homozygote (BB vs. AA), heterozygote (BA vs. AA), dominant (BB+BA vs. AA), and recessive (BB vs. BA+AA), which a ''A'' denotes a major allele; ''B'' denotes a minor allele. Between studies heterogeneity was tested by the Cochran Q-test, in which p-value less than 0.05 showed presence of heterogeneity. In addition, we used the I^2^ to detect the degree of heterogeneity between the included studies (I^2^=0-25%, no heterogeneity; I2=25-50%, moderate heterogeneity; I^2^\>50%, large heterogeneity). The study-specific ORs were pooled using a fixed-effect or random-effect model depending on the heterogeneity. When a Q test indicated P \<0.05 or I^2^ \>50%, a random-effect model was used; otherwise, a fixed-effect model was applied. The departure from Hardy-Weinberg equilibrium (HWE) in the controls was assessed using Pearson's χ^2^ test. Subgroup analyses based on ethnicity, source of controls (SOC), and genotyping methods were also performed. The stability of pooled results or influence of individual studies on the pooled ORs was tested through sensitivity analysis by omitting each study sequentially. Publication bias was estimated using the egg's funnel plot and Egger linear regression test. If the publication bias observed, the Duval and Tweedie ''*trim and fill*'' method was used to adjust the bias.

Results
=======

After a comprehensive literatures search we have identified 81 articles, then we reviewed all retrieved articles in accordance with the defined criteria. Of those articles, 62 articles were excluded due to be reviews, previous meta-analyses, case reports, letters, no detailed genotyping data, and duplicate publication. Finally, a total of 19 case-control studies in ten publications (Colakogullari et al., 2008; Hao et al., 2009; Hart et al., 2011; Hsia et al., 2014; Liang et al., 2011; Peddireddy et al., 2016; Seifart et al., 2005; Shih et al., 2005; Vogel et al., 2008; Zhang et al., 2015) were included in the meta-analysis. The details of each study were shown in [Table 1](#T1){ref-type="table"}. Of those studies, seven case-control studies with 1839 cases and 2,613 controls were on *-592A\>C*, five studies with 963 cases and 1558 controls on *-819T\>C*, and seven case-control studies with 1,282 cases and 1,960 controls on *-1082A\>G*. Among the included studies, eleven were preformed among the Asians and eight among the Caucasians. The sample size in cases ranged between 44 and 436. Three genotyping methods were utilized in the selected studies, including PCR-RFLP, PCR-SSP, and TaqMan.

*Quantitative Synthesis*

*IL-10 -592A\>C Polymorphism*

The summary of the meta-analysis of the association between *IL-10 -592A\>C* polymorphism and lung cancer risk were listed in [Table 2](#T2){ref-type="table"}. There was a significant association between the *-592A\>C* polymorphism and lung cancer risk under four genetic models, i.e., allele (CT vs. TT: OR= 1.14, 95% CI 1.03-1.25, p=0.007), homozygote (CC vs. AA: OR= 1.64, 95% CI 1.29-2.02, p≤0.001, [Figure 1A](#F1){ref-type="fig"}), heterozygote (CA vs. AA: OR= 1.26, 95% CI 1.06-1.50, p≤0.001), and dominant (CC+CA vs. AA: OR= 1.31, 95% CI 1.11-1.54, p=0.001, [Figure 1B](#F1){ref-type="fig"}). Stratified analysis by ethnicity revealed that there was a significant association between *IL-10 -592A\>C* polymorphism and lung cancer among Asians under four genetic models, i.e., allele (C vs. A: OR= 1.26, 95% CI 1.11-1.43, p≤0.001), homozygote (CC vs. AA: OR= 1.64, 95% CI 1.22-2.21, p=0.001), dominant (CC+CA vs. AA: OR= 1.25, 95% CI 1.04-1.49, p≤0.001), and recessive (CC vs. CA+AA: OR= 1.52, 95% CI 1.19-1.93, p=0.001), and Caucasians under four genetic models, i.e., homozygote (CC vs. AA: OR= 1.70, 95% CI 1.09-2.65, p=0.01), heterozygote (CA vs. AA: OR= 2.08, 95% CI 1.32-3.27, p=0.001), dominant (CC+CA vs. AA: OR= 1.76, 95% CI 1.13-2.71, p=0.01), and recessive (CC vs. CA+AA: OR= 1.52, 95% CI 1.19-1.93, p=0.001).

*IL-10 -1082A\>G and -819T\>C Polymorphisms*

The summary of the meta-analysis of the association between *-1082A\>G* and *-819T\>C* polymorphisms of *IL-10* gene and lung cancer risk were listed in [Table 2](#T2){ref-type="table"}. The pooled results showed that there was no significant association between*-1082A\>G* and *-819T\>C* polymorphisms of IL-10 gene and lung cancer in overall population under all five genetic models. Moreover, stratified analysis by ethnicity also revealed that there was not a significant association between *-1082A\>G* and *-819T\>C* polymorphisms of*IL-10* gene and lung cancer among Asians and Caucasians ([Table 2](#T2){ref-type="table"}).

*Heterogeneity test and Sensitivity analysis*

There was a significant in almost genetic models for *IL-10 -592A\>C* and *-819T\>C* polymorphisms. We have performed sensitivity analysis to detect the influence of each study on the pooled OR by deleting the single study and by deleting those studies did not accordance with HWE. However, sensitivity analysis suggested that a single study did not significantly change the pooled ORs, which indicated our meta-analysis results were robust and stable.

*Publication bias*

To determine the possible publication bias of the literature, we used the Begg's funnel plot and Egger test. The shapes of Begg's funnel plot did not show evidence of obviously asymmetrical for*IL-10 -592A\>C* and *-819T\>C* polymorphisms under all five genetic models and further confirmed by Egger test ([Table 2](#T2){ref-type="table"}). Although, Egger's test revealed a significant publication bias under the heterozygote genetic model (GA vs. AA: PBeggs = 0.45 and PEggers = 0.04, [Figure 2](#F2){ref-type="fig"}) for*IL-10 -1082A\>G* polymorphism. Therefore, the Duval and Tweedie non-parametric ''trim and fill'' method was applied to the publication bias result *IL-10 -1082A\>G*polymorphism. However, the outcomes showed that the current meta-analysis with and without ''*trim and fill*'' did not draw different results, indicating that our results were statistically reliable.

Discussion
==========

To date, several case-control studies that have been performed to evaluate the association of *IL-10*polymorphisms with the risk of lung cancer. However, the results are controversial due to the relatively small sample size of individual study, the different distributions of cases or healthy subjects, different lung cancer types, and the different genotyping methods. Meta-analysis as a powerful tool can provide more reliable results than a single study especially in explaining controversial conclusions. Thus, we performed this meta-analysis with larger sample size and subgroup to achieve a better understanding of the association of promoter region polymorphisms of *IL-10*gene with lung cancer risk. To the best of our knowledge, our meta-analysis, on the basis of 19 case-controls 4,084 cases and 6,131 controls is the largest and most comprehensive assessment to evaluate association of *IL-10* with lung cancer and the final results showed that*-592A\>C* polymorphism was associated with an increased lung cancer risk.

In 2012, Wang et al., (2012) in a meta-analysis based on three studies have evaluated the association of *IL-10 - 819C\>T*polymorphism and lung cancer. Their results showed that *IL-10 - 819C\>T* polymorphism was significantly associated with increased risk of lung cancer. However, Yu et al., (2013) in a meta-analysis of four case-controls studies found that the *IL-10 -819 C\>T* polymorphism was not significantly associated with lung cancer. In other meta-analysis, Peng et al., have reported that the *IL-10 1082G\>A*, *819C\>T* and *592C\>A* polymorphisms were significantly associated with risk of lung cancer (Peng et al., 2012). Although the previous meta-analyses have reported positive association between *IL-10* gene polymorphisms and lung cancer, the number of studies that they have included considerably smaller than that needed to receive the reliable results. Thus, those meta-analyses results should be interpreted with caution. Because, the number of studies included considerably smaller than that needed to receive the reliable results. However, our meta-analysis could offer adequate power to detect the association between *IL-10*gene polymorphisms and lung cancer. In addition, in this meta-analysis we have performed subgroup analysis by ethnicity and the significant associations were only found for *IL-10 -592A\>C* polymorphism among Asians and Caucasians. Therefore, *IL-10 -592A\>C* polymorphism may be important factor contributed to lung cancer development.

Between studies heterogeneity is one of the challenging issues in a meta-analysis (Aslebahar et al., 2019; Yazdi et al., 2017). In a meta-analysis, heterogeneity could explain by sample study design, size, genotyping methods, source of controls, cancer types, life style, and so on (Jafari Nedooshan et al., 2017; Mehdinejad et al., 2017; Sobhan et al., 2017a; Sobhan et al., 2017b). In the current meta-analysis there was significant heterogeneity for *-819T\>C* and *-1082A\>G* polymorphisms under almost genetic models. Thus, we conducted subgroup analyses based on ethnicity and the types of control groups. However, the results showed that the heterogeneity may have resulted due to something more than ethnicity and the types of control groups. Moreover, publication bias is another key factor that might affect the quality and reliability of a meta-analysis (Sadeghiyeh et al., 2017). There was publication bias for *IL-10 -1082A\>G*polymorphism under heterozygote genetic model might be due insufficient size of sample. Moreover, the ''*trim and fill*'' method results did not draw different results, indicating that the results were statistically reliable.

Although we conducted the most comprehensive meta-analysis based on all eligible studies, some limitations of this meta-analysis should be acknowledged. First, the number of eligible case-control studies included in this meta-analysis was small which limited statistical power to detect a potential association for those polymorphisms. Second, the sample size of some subgroups in the stratified analyses was limited, which may have reduced the statistical power to explore the association of the polymorphism with lung cancer susceptibility. Third, we have only included published studies in English in the meta-analysis. It is possible that some related unpublished studies and in other languages were missed; therefore, publication bias may have been present, even though statistical analysis indicated this not to be the case. Finally, lung cancer as most malignancies is a multifactorial disease that results from complex interactions between genetic and environmental factors. Our results were based on unadjusted estimates and a more precise analysis could be conducted if other covariates such as age, gender, smoking status, type of lung cancer, environmental factors, and lifestyle are available. Further evaluation of lung cancer risk should pay more attention to the potential interactions between gene-gene, gene-environment, and even between *IL-10 -592A\>C*, *-819T\>C*and*-1082A\>G* polymorphisms.

In summary, our findings suggest that *IL-10 -592A\>C*polymorphism might be risk factor for lung cancer, especially among Asians and Caucasians. However, *IL-10 -819T\>C* and *-1082A\>G* polymorphisms did not significantly associated with increased risk of lung cancer. Moreover, further studies with large sample sizes and well-designed multicenter analyses are required to clarify the association of *IL-10* polymorphisms with susceptibility of lung cancer.
